anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a novel staphlococcus aureus preparation and a preparation method thereof, and the staphlococcus aureus preparation is a novel staphlococcus aureus immunity preparation for treating golden staphylococcal infection. In the pathogenic bacteria of surgical acute pyogenic infection, the rate of staphylococcal infection accounts for the first position, which accounts for more than 88.9% of the total amount of examined bacteria. Because staphylococcus can rapidly generate drug resistance, the amount of the staphylococcus is increased without reduction. At present, 80 to 85% of the existing natural staphylococcus is drug resistant strains, and no effective drugs can control patient conditions. The staphlococcus aureus immunity preparation comprises the mycoprotein of staphylococcus aureus cgmccNo. 0671 and a toxoid biological preparation thereof, wherein the proportion of the mycoprotein (milligram) to toxoid (hemolytic unit) is (0.5 to 30) to (5 to 30). The staphlococcus aureus immunity preparation can be prepared into injections and can also be prepared into spraying agents or external skin liniment. The staphlococcus aureus immunity preparation is used for treating various pyogenic infections, such as trauma infections, surgical operation infections, staphlococcus aureus septicemia, youth acne, swollen, furuncle, osteomyelitis, mastitis, otitis media, etc.
Diabetic kidney disease (DKD) is one of the leading causes to develop end-stage kidney disease worldwide. Pericytes are implicated in the development of tissue fibrosis. However, the underlying mechanisms of pericytes in DKD remain largely unknown. We isolated and cultured primary pericytes and rat mesangial cells (HBZY-1). Western blot and qRT-PCR analysis were used to explore the role and regulatory mechanism of Integrin β8/transforming growth factor beta 1 (TGF-β1) pathway. We also constructed pericyte-specific Integrin β8 knock-in mice as the research objects to determine the role of Integrin β8 in vivo. We discovered that reduced Integrin β8 expression was closely associated with pericyte transition in DKD. Overexpressed Integrin β8 in pericytes dramatically suppressed TGF-β1/TGF beta receptor 1 (TGFBR1)/Smad3 signaling pathway and protected glomerular endothelial cells (GECs) in vitro. In vivo, pericyte-specific Integrin β8 knock-in ameliorated pericyte transition, endothelium injury and renal fibrosis in STZ-induced diabetic mice. Mechanistically, Murine double minute 2 (MDM2) was found to increase the degradation of Integrin β8 and caused TGF-β1 release and activation. Knockdown MDM2 could partly reverse the decline of Integrin β8 and suppress pericytes transition. In conclusion, the present findings suggested that upregulated MDM2 expression contributes to the degradation of Integrin β8 and activation of TGF-β1/TGFBR1/Smad3 signaling pathway, which ultimately leads to pericyte transition during DKD progression. These results indicate MDM2/Integrin β8 might be considered as therapeutic targets for DKD.
The modern-day Reiki (pronounced "ray-kee") practiced in the United States originated in Japan with Mikao Usui in the early 1900s. Reiki is a complementary and adjuvant therapeutic technique. Reiki, which is classified as an "energy healing therapy", is a technique of channeling universal energy in order to reduce stress, promote relaxation, and enhance well-being.
Wear particles generated from total joint replacements induce chronic osteolysis mediated by inflammatory upregulation, which leads to implant failure. Recent studies have suggested an important role of the gut microbiota in modulating the host's metabolism and immune system, leading to alterations in bone mass. Following gavage with P. histicola, micro-CT and HE staining revealed that osteolysis was significantly reduced in titanium (Ti)-treated mice. Immunofluorescence analysis revealed an increased macrophage (M)1/M2 ratio in the guts of Ti-treated mice, which decreased when P. histicola was added. P. histicola was also found to upregulate the tight junction proteins ZO-1, occludin, claudin-1, and MUC2 in the gut, reduce the levels of inflammatory factors IL-1β, IL-6, IL-8, and TNF-α, primarily in the ileum and colon, and decrease the expression of IL-1β and TNF-α and increase the level of IL-10 in the serum and cranium. Furthermore, P. histicola treatment resulted in a significant downregulation of CTX-1, RANKL, and RANKL/OPG. These findings demonstrate that P. histicola significantly mitigates osteolysis in Ti-treated mice by improving intestinal microbiota that repairs intestinal leakage and reduces systemic and local inflammation which in turn inhibits RANKL expression for bone resorption. P. histicola treatment may thus be therapeutically beneficial for particle-induced osteolysis.
Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Chartwell RX, LLC. at 1-845-232-1683.

Skin and Appendages:Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP), fixed drug eruptions, pruritis, rash and urticaria in postmarketing reports. 

Anticholinergic:Dry mouth. 

Central Nervous System:Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses. 

Cardiac System:QT prolongation, Torsade de Pointes.
The present invention discloses a medicine, in particular to a cold-fever tablet and the preparation method thereof. The cold-fever tablet is characterized in that a membrane tablet is made from following raw materials according to percentage by mass: 336g of radix isatidis, 252g of Spica Schizonepetae, 252g of bistort, 252g of kudzu root and 252g of Bupleurum. The uropatagia of the membrane tablet weighs 0.5g/tablet. Through market research and consultation of the invention, the original tablet (the uropatagia weighs 0.25g/tablet) is improved to the membrane tablet (the uropatagia weighs 0.5g/tablet). The invention avoids discoloration and flowering of a sugar tablet caused by moisture absorbance property of sucrose effectively, improves stability of products and enlarges using population. The successful development makes the medicine replace the original tablet, thereby being suitable for development of modern medicine and easy to be accepted for general patients.
Rapid access chest pain clinics have facilitated the early diagnosis and treatment of patients with coronary heart disease and angina. Despite this important service provision, coronary heart disease continues to be under-diagnosed and many patients are left untreated and at risk. Recent advances in imaging technology have now led to the widespread use of non-invasive computed tomography both to measure coronary artery calcium scores and undertake coronary angiography. However, this technology has not been robustly evaluated in any systematic approach. Using state-of-the-art multidetector computed tomography scanners, we propose to undertake a major multicentre randomized controlled trial to assess the added value of computed tomography imaging in over 4000 patients attending rapid access chest pain clinics across Scotland. This will define the most appropriate use of this emerging technology in the setting of diagnosing and treating patients with coronary heart disease and angina pectoris. This study will also lay the foundation for future studies to look at the potential prognostic value of this technology.
Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is a subtype of stroke that causes a great amount of disability, economic and social burden. This is particularly true in developing countries where it accounts for between 20% and 50% of all strokes. Pharmacological and surgical interventions have been attempted to diminish the mortality and disability derived from ICH, with unsuccessful results. Recently the use of Fluoxetine in addition to physical rehabilitation has been proven useful to improve motor recovery from cerebral infarct. The purpose of this study is to test whether a 3-month treatment with fluoxetine enhances motor recovery in non-depressed patients with acute intracerebral hemorrhage.

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial. This trial will recruit 86 patients with intracerebral hemorrhage of both sexes, ages \>18 years, from four Mexican hospitals. The patients will receive either 20mg of fluoxetine or a placebo once daily for 90 days. The primary outcome is the mean change in Fugl-Meyer Motor Scale score between inclusion (day 0) and day 90. The secondary outcomes will be changes in Barthel Index, Modified Rankin scale and National Institutes of Health (NIH) Stroke Scale. The outcomes will be measured at day 45±7days and at day 90, for a total of four visits with each subject (at screening and at 0, 45 and 90days).
FIELD: veterinary medicine.SUBSTANCE: group of inventions relates to veterinary medicine, namely to a composition for the treatment or delay of the progression of chronic kidney disease (hereinafter – CKD) in a cat. A dry or wet feed composition for pets contains effective amount of magnesium or its salt selected from acetate salt, TFA salt, formiate salt and glycinate salt for the treatment or delay of the progression of chronic kidney disease (CKD) in a cat in need of it, where the effective amount of magnesium or its salt is in the range between 50 mg/1000 kcal and 500 mg/1000 kcal, and the specified feed composition for pets additionally contains an additional active agent, which is a nutrient. A method for the treatment or delay of the progression of chronic kidney disease (CKD) in a cat (options) is proposed. A method for the diagnostics of a cat at risk of chronic kidney disease (CKD) for further treatment using a dry or wet feed composition for pets is proposed. A method for the treatment of a cat at risk of chronic kidney disease (CKD) is proposed. The use of a dry or wet feed composition for pets is proposed to treat or delay the progression of chronic kidney disease (CKD) in a cat in need of it, where the cat has a magnesium deficiency compared to a given reference value, and where the given reference value is based on the average level of magnesium in the blood of the control population. The use of magnesium levels in the blood as a biomarker for the prediction and/or quantitative description of chronic kidney disease in a cat, with its subsequent treatment, is proposed, where magnesium levels compared to the given reference value provide justification for the need to correct the diet for the treatment of chronic kidney disease in a cat in need of it, including the provision of a dry or wet feed composition for pets. A method for diagnosing chronic kidney disease (CKD) in a cat for further treatment using a dry or wet feed composition for pets is proposed. A method for the treatment of chronic kidney disease (CKD) in a cat is proposed.EFFECT: above-described composition and method are effective for the treatment or delay of the progression of chronic kidney disease (CKD) in a cat.31 cl, 7 dwg, 6 tbl, 3 ex
PROBLEM TO BE SOLVED: To obtain the subject pack capable of sticking fast to forehead, cheek and chin of face, absorbing movement of the face, preventing release from the skin, readily releasable from the skin after use, having high removability of cornoid lamella by making the pack include a pack agent layer and a moisture permeable/air permeable supporting layer. SOLUTION: This partial pack comprises (A) a pack agent layer (preferably comprising a water-soluble polymer preferably N-vinyl-2-pyrrolidone-vinyl acetate copolymer, or the like as a main component and (B) a moisture permeable/air-permeable supporting layer. A sheetlike pack 11 is positioned so that a depression bottom part and a projected part at the central part of the sheetlike pack are vertically located at the central part of a forehead 51. The sheetlike pack is pressed against the forehead and attached so as to cover the forehead 51. Since the sheetlike pack 11 is properly bent according to the shape of the forehead 51, the sheet is completely stuck along the shape of the forehead 51 to the skin, contacted and fixed.  The sheetlike pack 11 thus attached absorbs movements by the elasticity of the sheetlike pack 11 even if the skin of the forehead 51 is moved by some action in use and a movement to cause wrinkles on the skin of the circumference of the upper part of eyes 55 and eyebrows 56 occurs.
Autoimmune diseases only show local pathological damage, but more often systemic lesions. If not diagnosed and treated in time or poorly controlled, a risk of disability or even death as the course of the disease progresses. Studies have shown that B cells can present their own antigens to autoimmune T cells to promote the release of inflammatory factors, or they can differentiate into plasma cells to release autoantibodies, and play an important role in the occurrence and progression of autoimmune diseases. In recent years, it has become a major research focus to deplete B cells in patients or inhibit B cell function. This research focuses on CAR-T cells killing B cells. Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation of salivary and lachrymal glands, frequently accompanied by systemic symptoms. The presence of various autoantibodies such as rheumatoid factor (RF) and anti-SSA/SSB antibodies, as well as hypergammaglobulinemia, reflect B cell hyperactivity. About five percent of patients with SS develop malignant B cell lymphoma, usually of the mucosa-associated lymphoid tissue (MALT) type and most frequently located in the major salivary glands. This fully reflects the application prospects of CAR-T cells in autoimmune diseases.

Based on the current research progress, our center intends to conduct research on the safety and effectiveness of CD19/BCMA CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Dorzagliatin will be initiated and maintained at 75mg twice a day until the completion of the study. Meanwhile, all patients will also continue on regimen of metformin 500mg three times a day throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs.
Mitral valve prolapse (MVP) is a common condition characterized by bulging one or both mitral leaflets into the left atrium. Although mainly a benign cardiac condition, a subgroup of patients develop severe ventricular arrhythmias that are a significant cause of sudden cardiac death in young adults. Arrhythmic MVP is defined as the presence of mitral valve prolapse with or without mitral annulus disjunction (MAD) combined with frequent ventricular ectopy, complex ectopy or sustained ventricular arrhythmia in the absence of another well-defined arrhythmic substrate. In these patients, ventricular arrhythmias most commonly originate from the mitral annulus, papillary muscles and outflow tracts. Several risk markers have been proposed, but clinical risk stratification remains challenging. Ventricular arrhythmias in patients with arrhythmic mitral valve prolapse are associated with excess long-term mortality.

There is no established medical therapy to suppress ventricular arrhythmias and relieve arrhythmic symptoms in these patients, and conventional beta-blocker therapy is often unsuccessful for both. Invasive catheter ablation can suppress ventricular arrhythmias, and thus relieve symptoms, in a subset of patients. However, many patients have multifocal ventricular ectopy, often originating from deep in the myocardium or papillary muscles and not easily accessible for catheter ablation. Furthermore, recurrence of ventricular arrhythmias is common despite initial successful catheter ablation procedures. The only strategy to prevent sudden cardiac death for high-risk patients is to implant an implantable cardioverter defibrillator (ICD), but this approach does not provide any symptomatic relief. Thus, most patients with arrhythmic mitral valve prolapse lack effective treatment options with proven efficacy in clinical trials.

Flecainide is a class 1c antiarrhythmic drug with a potent sodium channel-blocking effect frequently used in atrial tachyarrhythmias. Flecainide was developed as a treatment for ventricular arrhythmias, but its use subsided due to safety concerns when used in patients with acute myocardial infarction. However, this knowledge stems from a patient population before modern revascularization strategies after myocardial infarction and is extrapolated to patients with other structural heart diseases. Lately, flecainide has been shown to be safe in patients with stable coronary artery disease. Furthermore, flecainide reduces ventricular arrhythmias in patients with premature ventricular complex (PVC)-mediated cardiomyopathy, arrhythmogenic cardiomyopathy and catecholaminergic polymorphic ventricular tachycardia without short-term adverse effects. However, flecainide has not been studied in arrhythmic mitral valve prolapse patients.

The main goal of FLECAPRO is to evaluate the effect and safety of adding flecainide to standard beta-blocker therapy to reduce the burden of ventricular arrhythmias in patients with arrhythmic mitral valve prolapse. We hypothesize that a flecainide-based strategy is superior to a beta blocker-based strategy to suppress ventricular arrhythmias in patients with arrhythmic mitral valve prolapse.
AimThe aim of this study is to summarize the spontaneous reports of tardive dyskinesia (TD) and extrapyramidal symptoms (EPSs) that occurred in Japan over the past decade. MethodsThe study analyzed TD and EPS cases reported in the Japanese Adverse Drug Event Report database between April 2011 and March 2021. The cases were stratified by the diagnoses of schizophrenia, bipolar disorders, and depressive disorders. ResultsIn total, 800 patients including a total of 171 TD cases and 682 EPS cases were reported in the JADER database across psychiatric diagnosis. The cases were caused by first-generation antipsychotics (FGA, TD: n = 105, EPS: n = 245) and second-generation antipsychotics (SGA, TD: n = 144, EPS: n = 598). The SGA were categorized based on Neuroscience-based Nomenclature (NbN) regarding pharmacological domain and mode of action, which were reported evenly as the offending agents. Among reported treatment and outcome in TD cases (n = 67, 37.6%) and EPS cases (n = 405, 59.3%), the relatively limited number of TD cases were reported as recovered/improved was also limited (n = 32, 47.8%) compared to those of EPS cases (n = 266, 65.7%). Some cases still had residual symptoms or did not recover fully (TD: n = 21, 31.3%, EPS: n = 77, 19.0%). CONCLUSION: Tardive dyskinesia and EPS have been widely reported in Japan over the past decade across psychiatric diagnoses and antipsychotic classes. LIMITATIONS: It is important to acknowledge the presence of reporting bias and the lack of comparators to accurately assess risks. Owing to the nature of spontaneous reporting, the estimation of prevalence is not feasible.
During its premarketing assessment, buspirone hydrochloride was evaluated in over 3500 subjects. This section reports event frequencies for adverse events occurring in approximately 3000 subjects from this group who took multiple doses of buspirone hydrochloride in the dose range for which buspirone is being recommended (i.e., the modal daily dose of buspirone hydrochloride fell between 10 mg and 30 mg for 70% of the patients studied) and for whom safety data were systematically collected. The conditions and duration of exposure to buspirone hydrochloride varied greatly, involving well-controlled studies as well as experience in open and uncontrolled clinical settings. As part of the total experience gained in clinical studies, various adverse events were reported. In the absence of appropriate controls in some of the studies, a causal relationship to buspirone hydrochloride treatment cannot be determined. The list includes all undesirable events reasonably associated with the use of the drug.

The following enumeration by organ system describes events in terms of their relative frequency of reporting in this data base. Events of major clinical importance are also described in the PRECAUTIONSsection.

The following definitions of frequency are used: Frequent adverse events are defined as those occurring in at least 1/100 patients. Infrequent adverse events are those occurring in 1/100 to 1/1000 patients, while rare events are those occurring in less than 1/1000 patients.
The invention discloses an anti-hypertension medicine compound preparation for reducing systolic pressure to the maximum degree. The anti-hypertension medicine compound preparation is prepared from, by weight, 50-400 parts of hydralazine hydrochloride, 10-80 parts of bendazol and 100-1,200 parts of drug carrier. Hydralazine hydrochloride and bendazol serve as medicine components to be mixed with the drug carrier to form the compound preparation. The anti-hypertension compound preparation prepared from hydralazine hydrochloride and an RAS inhibitor is convenient to take and safe to use. The compound preparation aims at controlling the systolic pressure in an omni-bearing mode, and absolutely diastolic pressure is necessarily reduced. The vasoconstrictor effect of ET can be relieved, the vasoconstrictor effect of AngII can be relieved, the pathological blood vessel proliferation effect of ET and AngII is relieved, and the compound preparation aims at main pathological neurohumor factors causing hypertension so far known, has the effect of reducing the systolic pressure to the maximum degree, and meanwhile has the effect of reducing the diastolic pressure.
The dose of nicardipine hydrochloride should be individually adjusted according to the blood pressure response beginning with 20 mg 3 times daily. The effective doses in clinical trials have ranged from 20 mg to 40 mg 3 times daily. The maximum blood pressure lowering effect occurs approximately 1 to 2 hours after dosing. To assess the adequacy of blood pressure response, the blood pressure should be measured at trough (8 hours after dosing). Because of the prominent peak effects of nicardipine, blood pressure should be measured 1 to 2 hours after dosing, particularly during initiation of therapy. (See PRECAUTIONS, Blood Pressure; INDICATIONS AND USAGE; CLINICAL PHARMACOLOGY, Effects in Hypertension.) At least 3 days should be allowed before increasing the nicardipine dose to ensure achievement of steady-state plasma drug concentrations.

###  Concomitant Use With Other Antihypertensive Agents, Beta-blockers

(See PRECAUTIONS, Drug Interactions.)